The ␣-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor is an ionotropic glutamate receptor that mediates fast excitatory synaptic transmission throughout the central nervous system. In addition to the glutamate binding site, allosteric modulatory sites on the receptor are inferred from the ability of synthetic compounds to affect channel function without interaction with the glutamate binding site. We have identified a novel class of potent, noncompetitive AMPA receptor antagonists typified by CP-465,022 and CP-526,427. The latter compound was radiolabeled and used to elucidate the pharmacology of one allosteric modulatory site. 3 H]CP-526,427 binding site does not seem to interact directly with the glutamate binding site but overlaps with that for another class of AMPA receptor antagonists, the 2,3-benzodiazepines. This binding site is distinct from that for the antagonist Evans blue and for several classes of compounds that modulate AMPA receptor desensitization. These results indicate the existence of at least two physically distinct allosteric sites on the AMPA receptor through which channel activity or desensitization is modulated.
Glutamate is the principal excitatory neurotransmitter in the mammalian central nervous system. Glutamatergic synaptic transmission is mediated by three major subtypes of ionotropic receptors: N-methyl-D-aspartate (NMDA), ␣-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), and kainate (Dingledine et al., 1999) . The AMPA receptor mediates fast glutamatergic synaptic transmission. Furthermore, increases in the efficacy of AMPA receptor-mediated synaptic responses underlie at least some forms of long-term potentiation, a process thought to be involved in memory and learning (Bear and Malenka, 1994) . This has engendered the hypothesis that compounds that increase AMPA receptor activity may be used to treat cognitive impairment (Staubli et al., 1994) . On the other hand, aberrant overactivation of AMPA receptors may play a role in epileptogenesis (Rogawski, 1993; Yamaguchi et al., 1993) and glutamate-induced neuronal death (Buchan et al., 1993; Madsen et al., 1994) . Significant advances in understanding the role of AMPA receptors in these pathological processes have come from studies with the glutamate binding site-competitive AMPA receptor antagonist, 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline (NBQX; Sheardown et al., 1990) . NBQX, and more recently other quinoxalinedione analogs (Namba et al., 1994; Ohmori et al., 1994) , have been found to be broadly effective at blocking seizures in a number of animal models (Namba et al., 1994; Shimizu-Sasamata et al., 1996) . These compounds also significantly reduce neuronal loss under experimental conditions, including middle cerebral artery occlusion, brief global cerebral ischemia, and traumatic brain and spinal cord injury (Buchan et al., 1991; Gill et al., 1992;  This work was supported by Pfizer, Inc.
ABBREVIATIONS: AMPA, ␣-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; NMDA, N-methyl-D-aspartate; NBQX, 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline; 466, inden-5-yl)-phenylamine; BCP-1, 1-(1,3-benzodioxol-5-ylcarbonyl)piperidine; CX-516, 1-(6-quinoxalinylcarbonyl)-piperidine; Co 102, 659, inden-8-one; Co 102, 685, inden-8-one; CP-465,022, 3-(2-Chloro-phenyl)-2-[2-(6-diethylaminomethyl-pyridin-2-yl)-vinyl]-6-fluoro-3H-quinazolin-4-one; CP-526,427, 2-{2-[3-(2-Chloro-phenyl)-6-fluoro-4-oxo-3,4-dihydro-quinazolin-2-yl]-vinyl}-nicotinonitrile; Co 102, 581, inden-8-one; YM-90K, 6-(1H-imidazol-1-yl)-7-nitro-2,3(1h,4h)-quinoxalinedione hydrochloride; BSS, balanced salt solution; RFUs, relative fluorescent units; CP-471,236, 6-Fluoro-3-(2-methyl-pyridin-3-yl)-2-[2-(2-methyl-thiazol-4-yl)-vinyl]-3H-quinazolin-4-one; MK-801, (ϩ)-5-methyl-10,11-dihydro-5-H-dibenzo [a,d] cycloheptan-5,10-imine. Sheardown et al., 1993; Shimizu-Sasamata et al., 1996; Teng Dong and Wrathall, 1996) . NBQX was initially believed to be specific for AMPA receptors based on radioligand binding (Sheardown et al., 1990) . However, it is now appreciated to have significant functional inhibitory activity at both kainate and AMPA receptors (Wilding and Huettner, 1996) , qualifying conclusions regarding the relative role of AMPA receptors in glutamate-induced neuron loss based on studies with this and related compounds. Nonetheless, the therapeutic potential of compounds such as NBQX has spurred efforts to discover novel compounds that affect AMPA receptor activity.
The search for compounds interacting with the AMPA receptor has resulted in the identification of several classes of allosteric modulators. GYKI-52,466 was identified as the first AMPA receptor antagonist not competitive at the glutamate binding site (Tarnawa et al., 1990 (Tarnawa et al., , 1992 . Structurally similar compounds, the 2,3-benzodiazepines, have now been shown to have a high degree of specificity for AMPA over kainate receptors (Paternain et al., 1995; Wilding and Huettner, 1995) . The dye Evans blue has also been shown to be a noncompetitive AMPA receptor antagonist with specificity for receptors containing the GluR1 or 2 subunit (Keller et al., 1993) . Several classes of compounds have been identified that potentiate AMPA receptor-mediated responses by inhibiting AMPA receptor desensitization. These include the benzothiadiazides, typified by cyclothiazide (Partin et al., 1993; Yamada and Tang, 1993) , and the benzoylpiperidines, typified by 1-(1,3-benzodioxol-5-ylcarbonyl)piperidine (BCP-1) and 1-(6-quinoxalinylcarbonyl)-piperidine (CX-516) (Arai et al., 1994 (Arai et al., , 1996 Lynch et al., 1997) . Recently, Konkoy et al. described two novel 2,3-benzodiazepine derivatives (Co 102,659 and Co 102,685) that potentiate rather than inhibit the activity of AMPA receptors (Konkoy et al., 1998) . The multiple effects of these different chemical classes on AMPA receptor activity suggests that the AMPA receptor contains at least one and possibly multiple allosteric binding sites through which activity can be modulated. Furthermore, the 2,3-benzodiazepine binding site may accommodate both agonists and inverse agonists, analogous to the benzodiazepine binding site on the ␥-aminobutyric acid A receptor. Determining the physical and functional relationship between these binding sites, and the mechanisms whereby these compounds effect AMPA receptor activity, remains an important research question.
To identify new compounds that inhibit AMPA receptor function, we screened a large chemical library for inhibitors of AMPA receptor mediated 45 Ca 2ϩ uptake in primary cultures of rat cerebellar granule neurons (assay described below). We discovered that the known anticonvulsant piraquilone (Koe et al., 1986; Fig. 1) effectively blocked this response in a manner not competitive with glutamate-site agonists (Chenard et al., 2000) . A medicinal chemistry effort to increase the potency and specificity of this lead for AMPA receptor inhibition led to the identification of a series of quinazolinones typified by CP-465,022 (Welch et al., 1998 ; and W. M. Welch, F. E. Ewing, J. Huang, F. S. Menniti, M. J. Pagnozzi, K. Kelly, P. A. Seymour, V. Guanowski, S. Guhan, M. R. Guinn, D. Critchett, J. Lazzaro, A. H. Ganong, and B. L. Chenard, submitted) . CP-465,022 inhibits AMPA receptormediated whole cell currents in rat cortical neurons in primary culture with an IC 50 value of 30 nM but only weakly inhibits NMDA, ␥-aminobutyric acid, or kainate receptormediated currents (Lazzaro and Ganong, 1998 . The functional activity and specificity of the quinazolinones for AMPA receptor inhibition in vitro and in vivo is described in detail in a manuscript in preparation (Menniti et al.) .
Materials and Methods
Chemicals. The chemical synthesis of 236 (Fig. 1 ) was accomplished by a route outlined in abstract form (Welch et al., 1998) 236 are atropisomers that were separated on a preparative scale by HPLC on a Chiracel OD column using 90:10 hexane/ethanol ϩ0.1% diethylamine as eluent. The physiochemical properties and stability of these compounds are described by Newell et al. (2000) . [ 3 H]CP-526,427 ( Fig. 1) was prepared as follows. Racemic 2-{2-[3-(2-chloro-4-iodo-phenyl)-6-fluoro-4-oxo-3,4-dihydro-quinazolin-2-yl]-vinyl}-nicotinonitrile was prepared by the condensation of 3-(2-chloro-4-iodo-phenyl)-6-fluoro-2-methyl-3H-quinazolin-4-one with 3-cyanopyridin-2-carboxaldehyde in tetrahydrofuran and trifluoroacetic anhydride catalyzed by anhydrous zinc chloride. The racemic compound was separated into its component atropisomers by chromatography on a chiral-phase HPLC column using a mixture of ethanol, acetone, and heptane with 0.1% diethylamine as eluent. Tritiated (S)-2-{2-[3-(2-chloro-phenyl)-6-fluoro-4-oxo-3,4-dihydro-quinazolin-2-yl]-vinyl}-nicotinonitrile was prepared by the reductive hydrogenolysis of (S)-2-{2-[3-(2-chloro-4-iodophenyl)-6-fluoro-4-oxo-3,4-dihydro-quinazolin-2-yl]-vinyl}-nicotinonitrile in ethyl acetate with tritium gas using palladium on carbon as the catalyst. GYKI-52,466 (Chenard et al., 1993) , Co 102,685, Co 102, 659, and Co 102,581 (Xia et al., 1997) , and YM-90K (Ohmori et al., 1994) were synthesized as described previously. All other compounds were obtained from commercial sources.
Primary Cultures of Rat Cerebellar Granule Neurons. Primary cultures of rat cerebellar granule neurons were prepared as described previously (Parks et al., 1991) . Cerebella were removed from 7-to 8-day-old Sprague-Dawley rats, minced into 1-mm pieces, and incubated for 15 min at 37°C in Ca 2ϩ -Mg 2ϩ free Tyrode's solution containing 0.1% trypsin. The tissue was then triturated using a fine-bore Pasteur pipette. The cell suspension was plated onto poly-D-lysine coated 96-well tissue culture plates at 10 5 cells per well. Medium consisted of minimal essential medium with Earle's salts, 10% fetal calf serum (Hyclone Laboratories, Logan, UT), 2 mM L-glutamine, 100 U/ml penicillin-streptomycin, and 25 mM KCl. After 24 h, the medium was replaced with fresh medium containing 10 M cytosine arabinoside to inhibit cell division. Cultures were used at 5 to 8 days in vitro.
45

Ca
2؉ Uptake. Neurons in poly-D-lysine-coated 96-well plates were preincubated for 30 min with different concentrations of compounds in balanced salt solution (BSS; 115 mM NaCl, 5.4 mM KCl, 0.96 mM NaH 2 PO 4 , 1.8 mM CaCl 2 , 11 mM d-glucose, and 25 mM HEPES, pH 7.3). They were then exposed at room temperature to 100 M kainate or NMDA in BSS containing 10 M glycine, 0.5 mM dithiothreitol, and 0.5 Ci
45
Ca 2ϩ (final specific activity, 2.78 Ci/ mol) in a volume of 100 l/well. After 10 min, the neurons were then rapidly washed five times with 200 l/well of ice-cold BSS containing 5 mM EGTA. Neurons were then lysed in 30 l/well of 0.6% Triton X-100 and radioactivity in aliquots of the lysate were measured with a TopCount microtiter scintillation counter (Packard Instrument Co., Downers Grove, IL). Forebrains of adult male Sprague-Dawley rats were homogenized in 0.32 M sucrose at 4°C. The crude nuclear pellet was removed by centrifugation at 1,000g for 10 min, and the supernatant centrifuged at 17,000g for 25 min. The resulting pellet was resuspended in 5 mM Tris acetate, pH 7.4, at 4°C for 10 min to lyse cellular particles and again centrifuged at 17,000g. The resulting pellet was washed twice in Tris acetate, resuspended at 10 mg of protein/ml and stored at Ϫ20°C until use. Immediately before binding assays, membranes were thawed, homogenized, and diluted to 0.5 mg of protein/ml with 50 mM Tris⅐HCl, pH 7.4. Scatchard analyses were performed by incubating different concentrations of radioligand with membranes. For competition assays, compounds were added at various concentrations followed by 3 nM [ 3 H]CP-526,427 (specific activity, 24.36 Ci/mmol). After incubation for 20 min at 30°C in a shaking water bath, samples were filtered onto Whatman GFB glass fiber filters using a MB-48R Cell Harvester (Brandel Research and Development Laboratories, Gaithersburg MD). Filters were washed for 10 s with ice-cold Tris⅐HCl buffer and the radioactivity trapped on the filter quantified by liquid scintillation counting. 
Measurement of [Ca
Results
A medicinal chemistry effort to increase the potency and specificity of piraquilone for AMPA receptor inhibition resulted in the identification of a series of novel quinazolinone AMPA receptor antagonists (Fig. 1) . To elucidate the pharmacology of these compounds, one of the most potent analogs, CP-526,427, was radiolabeled and a series of ligand binding studies was undertaken. Scatchard analysis of [ 3 H]CP-526,427 binding was performed in triplicate on four preparations of rat forebrain membranes. An example of results from one of these experiments is depicted in Fig. 2. [ 3 H]CP-526,427 binds in a saturable manner to rat forebrain membranes with a K d value of 3.3 Ϯ 0.3 nM and a B max value of 7.0 Ϯ 3.5 pmol/mg of protein (means Ϯ S.E.M. from the four membrane preparations). These data are best fit by a single binding site model; however, the possibility of a second lowaffinity binding site cannot be ruled out. In these experiments, the nonspecific binding was 30 to 40% at ligand concentrations similar to the K d value. This relatively high value, in light of the apparent high affinity for a specific binding site, most likely results from the lipophilicity of CP-526,427 (calculated LogP ϭ 3.7) and the propensity for nonspecific protein binding exhibited by this (Fig. 4) . CP-465,022 at 100 nM inhibits greater than 90% of the kainate-induced 45 Ca 2ϩ uptake in the rat cerebellar granule neuron cultures (Fig. 4) . However, the compound at this concentration is much less effective for inhibition of 45 Ca 2ϩ uptake induced by 100 M NMDA (approximately 15% inhibition), whereas 1 M MK-801 completely inhibits the NMDA-induced response (Fig. 4) . . At the end of 10 min, the reaction was stopped and the amount of radioactivity accumulated was determined as described under Materials and Methods. Ca 2ϩ uptake in the cerebellar granule neuron cultures in a concentration dependent manner (Fig. 3A) . In contrast, the corresponding R-atropisomers (CP-465,021 and CP-471,237, respectively) have 100-fold lower potencies. In fact, the IC 50 values for inhibition of the AMPA receptor-mediated functional response corresponds closely with potency for displacement of [ 3 H]CP-526,427 binding ( (Fig. 3, top) , cyclothiazide, BCP-1, and CX-516 ( Fig. 3, top ; Table 1 ). The potency of GYKI-52,466 in the binding assay is similar to that for inhibition of AMPA receptor mediated 45 Ca 2ϩ uptake in rat cerebellar granule neurons (Fig. 3, bottom ; Table 1 ).
We also examined the activity of structurally related 2,3-benzodiazepine derivatives, some of which potentiate instead of inhibit AMPA receptor activity. Co 102,581 inhibited in a concentration dependent manner the increase in [Ca 2ϩ ] i induced by 32 M AMPA in rat cerebellar granule neurons (Fig. 5, top) with an IC 50 value of 30.0 M. This compound is approximately 3-fold less potent than GYKI 52,466 (IC 50 ϭ 9.2 M) and 400-fold less potent than CP-465,022 (IC 50 ϭ 0.074 M) in this assay (Fig. 5, top) . In contrast, Co 102,685 (Fig. 5, top, and Fig. 6 ) and Co 102,659 (Fig. 5, top) significantly potentiated the increase in [Ca 2ϩ ] i induced by 32 M AMPA in rat cerebellar granule neurons. Co 102,685 was both more potent and efficacious than Co 102,659; however, IC 50 values could not be calculated in this assay because poor solubility at concentrations higher than 32 M precluded determination of concentrations yielding maximal effect. Nonetheless, the magnitude of the potentiation of AMPA receptor responses over the concentration range tested is similar to that reported by Konkoy et al. for potentiation of AMPA-stimulated whole-cell currents in rat cortical neurons in primary culture (Konkoy et al., 1998 (Fig. 5, bottom) . 1314 (Sheardown et al., 1990) . GYKI-52,466, the prototype of the 2,3-benzodiazepine AMPA receptor antagonists, inhibited AMPA receptor activation-induced 45 Ca 2ϩ uptake in rat cerebellar granule neurons with an IC 50 of 14 M, similar to the potency reported by others in functional assays . All of the compounds identified to date that inhibit AMPA receptor desensitization also require micromolar concentrations for efficacy. The potency of CP-526,427 enabled development of a radioligand and binding assay to elucidate the pharmacology of an allosteric modulatory site on the AMPA receptor that is discussed below.
[ 3 H]CP-526,427 binds with high affinity to a presumed single site on rat forebrain membranes. Scatchard analysis indicates a K d value of 3.3 nM. The K d value agrees closely with the IC 50 value for CP-526,427 inhibition of AMPA receptor activation-induced 45 Ca 2ϩ uptake in rat cerebellar granule neurons (present study) and AMPA receptor mediated whole cell currents in cortical neurons (Lazzaro and Ganong, 1998 [ 3 H]AMPA labels two binding sites in rat forebrain membranes: a high-affinity, low-abundance site and a low-affinity, high-abundance site (Honoré et al., 1982) . The ability to detect the low affinity [
3 H]AMPA binding site is increased when incubations are performed at low temperature and in the presence site of the chaotropic agent thiocyanate (Honoré and Drejer, 1988) 466) , four 022), 659, 685, 581) experiments in which each condition was replicated in four or eight wells. Bottom, compounds were incubated at the indicated concentrations with rat forebrain membranes and 3 nM [ 3 H]CP-526,427 and bound radioactivity determined. Nonspecific binding was determined for each point in parallel incubations containing 10 M CP-465,022 and specific binding was calculated as total minus nonspecifically bound radioactivity. Percent of maximum binding of [
3 H]CP-526,427 was then calculated as: (Specific bound Ϫ nonspecific bound)/specific bound when no added drug) ϫ 100. Each point is the mean (Ϯ S.E.M) from two or three experiments where each condition was determined in triplicate. (Weiser et al., 1996) . The finding of the present study, that GYKI-52,466 but not Evans blue displaces [ 3 H]CP-526,427 binding, is consistent with this conclusion. Thus, there seem to be at least two sites through which AMPA receptor activity can be allosterically inhibited: the quinazolinone/2,3-benzodiazepine site and the Evans blue site.
Several classes of synthetic compounds have also been identified that allosterically modulate AMPA receptor desensitization. In the present study, the benzothiadiazide cyclothiazide failed to displace [ 3 H]CP-526,427 binding. It was originally hypothesized that the inhibitory effect of GYKI-52,466 resulted from increased desensitization through an interaction with the site also modulated by cyclothiazide (Zorumski et al., 1993) . However, analyses of the functional effects of the 2,3 benzodiazepines on channel gating kinetics indicated that the compounds do not directly effect desensitization Partin and Mayer, 1996) . Furthermore, Partin and Mayer found that a point mutation of GluR1 (S750Q) abolishes the effect of cyclothiazide to block AMPA receptor desensitization but has no effect on the ability of GYKI-52,466 to inhibit receptor activity. The binding data presented here corroborate this earlier functional data confirming that the quinazolinone/2,3-benzodiazepine binding site is distinct from the site of action of the benzothiadiazides. The benzoylpiperidines BCP-1 and CX-516 also inhibit AMPA receptor desensitization; however, differential effects on flip and flop splice variants of the AMPA receptor and on agonist affinity suggest that this class interacts with a site on the AMPA receptor that is different from that of the benzothiadiazides (Kessler et al., 1998) . In the present study, the benzopyridines also failed to displace [ 3 H]CP-526,427 binding, suggesting that these compounds interact with yet another unique site on the AMPA receptor.
Recently, Konkoy et al. demonstrated that the 2,3-benzodiazepine derivatives, Co 102,659 and Co 102,685, potentiate AMPA receptor activity (Konkoy et al., 1998) . This observation raised the possibility that the 2,3-benzodiazepine binding site might accept agonists (Co 102,659 and Co 102,685) as well as inverse agonists 466) . In the present study, Co 102,659 and Co 102,685 were found to potentiate the AMPA receptor activation-dependent increase in [Ca 2ϩ ] i in rat cerebellar granule neurons. The potency and efficacy was similar to that reported for potentiation of whole-cell currents in rat cortical neurons. However, these compounds failed to displace [ 3 H]CP-526,427 binding from rat forebrain membranes at similar concentrations. Thus, despite the structural similarities, the ability of Co 102,659 and Co 102,685 to potentiate AMPA receptor responses may be mediated by an interaction with a site distinct from that through which the antagonist 2,3-benzodiazepines inhibit AMPA receptor responses. In summary, [
3 H]CP-526,427 binds to an allosteric site on the AMPA receptor. Both the quinazolinones disclosed here and the 2,3 benzodiazepines inhibit AMPA receptor activity through an interaction with this site. This site seems to be distinct from the glutamate binding site as well as the one or more sites on the receptor through which synthetic compounds modulate AMPA receptor desensitization. The localization of the [ 3 H]CP-526,427 binding within the three-dimensional structure of the AMPA receptor, and how interaction of molecules with this site inhibits receptor activity, remains to be determined. The three dimensional structure of the ionotropic glutamate receptors is beginning to be understood (Paas, 1998) . The flip/flop module within the large extracellular loop between the second and third membrane-spanning domains is a native allosteric regulator of AMPA receptor kinetics and desensitization (Sommer et al., 1990) . Partin et al. (1995) have determined that a single amino acid within the flip/flop module is critical for the effect of cyclothiazide on AMPA receptor desensitization. This suggests that the cyclothiazide-binding site is part of or interacts closely with the flip/flop module and raises the possibility that other desensitization modulators act in this region. It is also noteworthy that allosteric inhibitors of NMDA receptors, such as ifenprodil and CP-101,606, seem to reside in the distal N terminus of the NR2B subunit (Chenard and Menniti, 1999) , suggesting that this region of the NMDA receptor can be involved in modulation of channel activity. Similarly, the analogous region of the AMPA receptor may be a site of action for allosteric inhibitors, given the similar structural organization of AMPA and NMDA receptors. Tools such as [ 3 H]CP-526,427 will be valuable in further understanding the structure/function relationships involved in regulating AMPA receptor activity.
